SB
SYRS

Samsara BioCapital’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Samsara BioCapital’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,786,427
Closed -$3.84M – 46
2024
Q3 		$3.84M Hold
1,786,427
– – 0.74% 24
2024
Q2 		$9.22M Hold
1,786,427
– – 1.93% 15
2024
Q1 		$9.56M Hold
1,786,427
– – 1.48% 16
2023
Q4 		$13.9M Buy
1,786,427
+904,977
+103% +$3.1M 2.16% 12
2023
Q3 		$3.48M Hold
881,450
– – 1.07% 25
2023
Q2 		$2.78M Hold
881,450
– – 0.49% 26
2023
Q1 		$2.35M Hold
881,450
– – 0.49% 32
2022
Q4 		$3.16M Hold
881,450
– – 0.68% 26
2022
Q3 		$5.68M Buy
881,450
+691,488
+364% +$5.62M 1.32% 20
2022
Q2 		$1.83M Hold
189,962
– – 0.49% 36
2022
Q1 		$2.26M Sell
189,962
-28,958
-13% -$518K 0.57% 37
2021
Q4 		$6.24M Hold
218,920
– – 1.21% 20
2021
Q3 		$8.62M Hold
218,920
– – 1.35% 20
2021
Q2 		$10.6M Hold
218,920
– – 1.31% 19
2021
Q1 		$14.8M Hold
218,920
– – 2.72% 11
2020
Q4 		$21.8K Buy
218,920
+78,125
+55% +$7.13M 2.2% 6
2020
Q3 		$11.6M Sell
140,795
-16,395
-10% -$1.86M 3.24% 10
2020
Q2 		$15.9M Sell
157,190
-15,470
-9% -$1.39M 5.1% 8
2020
Q1 		$9.6M Hold
172,660
– – 5.52% 8
2019
Q4 		$11.3M Hold
172,660
– – 5.39% 7
2019
Q3 		$17M Hold
172,660
– – 11.58% 3
2019
Q2 		$15.2M Buy
172,660
+66,666
+63% +$4.64M 10.06% 4
2019
Q1 		$9.69M Hold
105,994
– – 7.61% 7
2018
Q4 		$5.9M Buy
+105,994
New +$8.05M 5.67% 7

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Samsara BioCapital's SYRS Position: Q4 2024 in Review

Samsara BioCapital sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 1,786,427 shares — an estimated $3.84M sold.

Samsara BioCapital first reported a position in SYRS in Q4 2018 and held it in 24 quarters. The position peaked at $17M in Q3 2019. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

  • Samsara BioCapital reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Samsara BioCapital sold 1,786,427 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $3.84M.
  • Samsara BioCapital first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 24 quarters.
  • Samsara BioCapital's Syros Pharmaceuticals, Inc. Common Stock position peaked at $17M in Q3 2019.
  • 44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Samsara BioCapital's 13F filing for Q4 2024, filed 14 Feb 2025.